Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG), a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, today announced promising interim preclinical data supporting the ongoing development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data highlights ALPHA-1062’s potential benefits in addressing mTBI caused by repetitive blast trauma, a common and significant injury in military settings. Blast-induced mTBI is recognized as a signature injury among soldiers, with brain damage resulting from exposure to explosive devices and artillery blasts being widespread.
Alpha Cognition Inc. (ACI), a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, recently reported positive interim data from an ongoing preclinical study evaluating ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI) caused by repetitive blast trauma. This study, supported by the U.S. Department of Defense (DoD), is conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research, affiliated with the University of Washington and the Veterans Administration.
ALPHA-1062, a novel acetylcholinesterase inhibitor, has previously shown significant functional and neuropathological protection following a single moderate traumatic brain injury. This second preclinical study, conducted in a rodent model, investigates the compound’s effectiveness after three consecutive days of blast-induced mTBI. Interim results have demonstrated that ALPHA-1062 administration leads to a reduction in the neuropathology associated with mTBI. Specifically, the study revealed that the compound reduced neuroinflammation markers and damage caused by the blast trauma.
Notable findings from the study include the high-dose ALPHA-1062’s ability to lower myeloid cell activation (CD68) across multiple brain regions one month after the blast. Additionally, ALPHA-1062 reduced midbrain astrogliosis, a process where astrocytes (brain cells) increase in size and number in response to injury. These results suggest a protective effect of ALPHA-1062, further supporting its potential for treating acute mild traumatic brain injury.
Denis Kay, ACI’s Chief Scientific Officer, commented on the findings, stating, “These outcomes indicate a protective effect of ALPHA-1062 and a reduction in neuropathology, providing further support for its continued development for treating acute mTBI.” Further analysis of neuropathology and neurobehavioral data is underway, with the final study report expected in Q2 2025.
In addition to its potential for treating mTBI, ALPHA-1062 is being developed as a treatment for Alzheimer’s disease. Its active metabolite uniquely targets neuronal nicotinic receptors, particularly the alpha-7 subtype, which is believed to enhance cognitive function. ALPHA-1062 is also being evaluated in combination with memantine to treat moderate to severe Alzheimer’s dementia.
An intranasal formulation of ALPHA-1062 has shown promising results in preclinical models of moderate TBI, preserving brain structure and function and improving recovery from injury. This formulation is currently being evaluated in a military-relevant model of repeated mild TBI, sponsored by the U.S. Department of Defense.
Alpha Cognition Inc. remains dedicated to developing new treatments for patients suffering from neurodegenerative diseases and mTBI, for which there are currently no approved treatments.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, including Alzheimer’s disease and cognitive impairment due to mild traumatic brain injury (mTBI). The company’s lead product, ALPHA-1062, is a new-generation acetylcholinesterase inhibitor aimed at treating Alzheimer’s disease with minimal gastrointestinal side effects.
